Becaplermin
Also known as: Becaplermin, becaplermin gel, PDGF-BB gel, PDGF‑BB, Regranex, rhPDGF-BB
Source Becaplermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Topical gel formulation of recombinant human PDGF‑BB (becaplermin) approved for treatment of diabetic foot ulcers that have failed to heal with standard care.
Mechanism of Action
Binds PDGF receptors on fibroblasts, keratinocytes and smooth‑muscle cells, activating MAPK/PI3K pathways that stimulate cell proliferation, migration and extracellular‑matrix synthesis, thereby accelerating wound repair.
Routes of Administration
Goals & Uses
- Diabetic foot ulcer healingWound HealingHigh
- Granulation tissue formationTissue RepairHigh
- Chronic wound managementWound HealingModerate
- Accelerate diabetic foot ulcer closureWound HealingHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Hypersensitivity to becaplermin or parabensAllergic/immunologicHigh
- Neoplasm at application siteOncologicHigh
- Application near wounds with inadequate blood supplyVascularModerate
- Known hypersensitivity to becaplermin or any gel componentAllergyModerate
Adverse Effects
- Skin irritationDermatologicCommon
- Potential increased risk of malignancySystemic RiskRare
- Application site erythemaLocalCommon
- Pain at application siteLocal Skin ReactionCommon
- Local erythemaDermatologicCommon
- Increased cancer mortality riskOncologicRare
- Infection at wound siteInfectiousUncommon
Drug Interactions
- Topical antiseptics (e.g., povidone-iodine, hydrogen peroxide)Moderate
- Systemic immunosuppressants (e.g., corticosteroids)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients < 18 yearsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with diabetic foot ulcersIndicationAbsolute
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionUnapprovedNot authorized in the European Union.
- United StatesApprovedApproved: Diabetic foot ulcer (non‑healing)Approved under NDA 021917; marketed as Regranex.
- United KingdomUnapprovedNo marketing authorization; may be accessed via compassionate use.
FDA‑approved (Regranex) for diabetic foot ulcer healing; contraindicated in patients with active malignancy or known hypersensitivity; boxed warning for potential increased risk of cancer with prolonged use.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Becaplermin?
Topical gel formulation of recombinant human PDGF‑BB (becaplermin) approved for treatment of diabetic foot ulcers that have failed to heal with standard care.
What is Becaplermin used for?
Becaplermin is educationally associated with: Diabetic foot ulcer healing, Granulation tissue formation, Chronic wound management, Accelerate diabetic foot ulcer closure. Educational only — not medical advice.
How is Becaplermin administered?
Recorded routes of administration: Topical.
What are the potential side effects of Becaplermin?
Reported adverse effects include: Skin irritation, Potential increased risk of malignancy, Application site erythema, Pain at application site, Local erythema, Increased cancer mortality risk, Infection at wound site. This list is not exhaustive — consult a qualified clinician.
Who should avoid Becaplermin?
Recorded contraindications: Active malignancy, Hypersensitivity to becaplermin or parabens, Neoplasm at application site, Application near wounds with inadequate blood supply, Known hypersensitivity to becaplermin or any gel component. Consult a qualified clinician before use.